NCT06999434PHASE1RecruitingAccepts Healthy Volunteers
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Yale University
Start Date
5/5/2025
Completion Date
5/5/2030
Summary
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Eligibility Criteria
Age Range: 18 years to 90 years
Inclusion:
1. Male and Female subjects must be ≥18 and \<90 years of age;
2. Able to understand and provide informed consent prior to study procedures
3. Must be in good health
Exclusion:
1. Less than 18 years of age;
2. Pregnant or breastfeeding;
3. Any significant systemic illness or unstable medical condition;
4. Pre-existing medical conditions or claustrophobic reactions;
5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months);
6. History of a bleeding disorder or are currently taking anticoagulants.
Interventions
DRUG
[ 18F]3F4AP
DRUG
[18F]MK6240
DRUG
[11C]PIB
Conditions
Demyelinating DisordersMCIAlzheimer's Disease (AD)MS (Multiple Sclerosis)SCI - Spinal Cord InjurySpinal Radiculopathy
Locations
Yale University PET Center
New Haven, Connecticut 06510
United States